Comparative Pharmacology
Head-to-head clinical analysis: AJOVY versus UBRELVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AJOVY versus UBRELVY.
AJOVY vs UBRELVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ajovy (fremanezumab) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the CGRP receptor, thereby inhibiting CGRP-mediated neurogenic vasodilation and pain transmission in trigeminal sensory neurons.
Calcitonin gene-related peptide (CGRP) receptor antagonist; blocks CGRP-mediated vasodilation and nociception.
AJOVY (fremanezumab-vfrm) is administered subcutaneously at a dose of 675 mg once every 3 months (quarterly) or 225 mg once monthly. The injection volume is 1.5 mL for the 225 mg dose and 4.5 mL for the 675 mg dose, administered as three separate injections of 225 mg each.
100 mg orally once, may repeat once after at least 2 hours if needed; maximum 200 mg per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 31 days (range 23-37 days). This long half-life supports monthly subcutaneous dosing.
Terminal elimination half-life is approximately 50 hours, supporting once-daily dosing.
Renal excretion of intact antibody is minimal; metabolized via catabolism to peptides and amino acids. Approximately 100% of elimination is via intracellular degradation (proteolysis) and biliary excretion of metabolites, with negligible renal excretion.
Primarily hepatic metabolism via CYP3A4, with 42% of dose excreted in feces (6% unchanged) and 26% in urine (1% unchanged).
Category C
Category C
CGRP Antagonist
CGRP Antagonist